vTv Therapeutics (Nasdaq: VTVT) shares thwarted in the after-market hours to -37.71% to $1.85 after the company revealed that it had signed a worldwide license agreement with Anteris Bio for the world’s first clinical-stage Nrf2 activator compound, HPP971. The biotech investment firm Aditum Bio, co-founded in 2019 by former Novartis executives Joe Jimenez and Dr. Mark Fishman, will focus on developing HPP971 as a new treatment for renal diseases.
HPP971 comes from the company’s portfolio of promising Nrf2 compounds that offer a well-established oral, small-molecule activator of the Nrf2 pathway. Phase 1 studies involving HPP971 have been completed two times to date. In exchange for worldwide development and commercialization rights for the compound, Anteris will pay vTv an upfront payment of $2 million, and vTv may collect milestones worth up to $151 million, in addition to royalties on net sales at a low double-digit rate. Additionally, vTv will be given a minority equity stake in Anteris Bio.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Sponsored
